Résultats de la recherche
10
Tout
DEMIRE achieves 2024 guidance for rental income and FFO
20 mars 2025 02h30 HE
|
DEMIRE Deutsche Mittelstand Real Estate AG
DEMIRE achieves 2024 guidance for rental income and FFO
Rental income: EUR 65.3m (prev: EUR 78.5m); FFO I: EUR 23.8m (prev: 36.7m) in line with expect.
DEMIRE erreicht Prognose 2024 für Mieterträge und FFO
20 mars 2025 02h30 HE
|
DEMIRE Deutsche Mittelstand Real Estate AG
DEMIRE erreicht Prognose 2024 für Mieterträge und FFO
Mieteinnahmen: EUR 65,3 Mio. (Vorj: EUR 78,5 Mio.); FFO I: EUR 23,8 Mio. (Vorj: EUR 36,7 Mio.)
PaayaTech Announces the Release of New Business Reporting Software ReportLinx
09 janv. 2025 09h00 HE
|
PaayaTech Inc.
ReportLinx is a web-based report automation tool that simplifies report creation, reduces errors, and automates repetitive tasks.
Treasure Global Inc. Reports First Quarter Fiscal Year 2025 Financial Results
18 nov. 2024 08h30 HE
|
Treasure Global Inc.
NEW YORK and KUALA LUMPUR, Malaysia, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ: TGL) (“Treasure Global” or the “Company”), a leading e-commerce platform operator, had on...
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
15 nov. 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
CSX Corporation Announces Date for Third Quarter Earnings Release and Earnings Call
24 sept. 2024 12h00 HE
|
CSX Corporation
JACKSONVILLE, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- CSX Corp. (NASDAQ: CSX) will release third quarter financial and operating results after the market close on Wednesday, October 16, 2024. This...
Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
03 avr. 2024 04h00 HE
|
Molecure
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare...
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
13 mars 2024 07h00 HE
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
DELÅRSRAPPORT 3. KVT. 2023: FORVENTNING FORBEDRET AF SOLIDT KVARTAL
15 nov. 2023 01h30 HE
|
DFDS A/S
SELSKABSMEDDELELSE NR. 37/2023 Bedre end forventet EBITDA for 3. kvartal på DKK 1,6 mia.Stærk højsæson for passagererFragtresultat som forventet lavere end sidste årCash flow yderligere...
Q3 2023 INTERIM REPORT: OUTLOOK FIRMED UP BY SOLID QUARTER
15 nov. 2023 01h30 HE
|
DFDS A/S
ANNOUNCEMENT NO. 37/2023 Q3 EBITDA of DKK 1.6bn was ahead of expectationsStrong passenger high seasonFreight performance as expected below last yearCash flow further improvedEBITDA...